Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

Good morning. Today is Friday, January 24th. I'm Julie Morgan. Allurian soars pre-market.

Star Dust breaks ground but shares plunge, and OpenAI debuts a new shopping tool. Allurion is up 83% in

pre-market action after ending Thursday's regular session, 21% higher. Allurian announced plans to

conduct a clinical study of its gastric balloon weight loss product in combination with GLP1 drugs.

The company noted that while studies have shown GLP1 use can lead to a significant reduction

in muscle mass, patients treated with the Illurian balloon were able to maintain an even

increase muscle mass. Both Novo's simaglutide and Eli Lilly's tear

Zepatide are GLP1 receptor agonist drugs. Novo markets simaglutide for diabetes as OZempic

and for weight loss as Wigo v, while Lilly markets tear Zepatide for diabetes as

Manjaro and for weight loss as Zepbound.

Other companies working on GLP1 drugs include AstraZeneca, Amgen, Pfizer, Alt-immune and Viking

Therapeutics, among others.

Stardust Power officially broke ground on its $1.2 billion lithium refinery in Muskogee, Oklahoma,

but shares close lower by 36.3% on Thursday.

The project will be developed in two phases,

with phase one focused on constructing a production line capable of producing up to 25,000 metric tons per year, and Phase 2 would add a second

production line, bringing the total capacity to 50,000 tons per year. The company's CEO said that

the lithium refinery will be crucial for addressing U.S. national security, as well as concerns

about the supply chain. They went on to say that by

unshoring critical mineral manufacturing, they're helping to sustain America's energy leadership.

Stardust is reversing some of Thursday's losses. SDST is up 13% pre-market.

...